Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Blaine Carmichael

Physician Assistant Seguin, TX Physician Assistant

NPI 1386633121 CMS profile 10890969

1300 N State Highway 46, Seguin, TX 78155

Open in the dashboard

General payments

$15,754

202 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Blaine Carmichael of Seguin, TX is reported in the CMS Open Payments database as having received $15,754 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $88 1
2024 General $395 18
2023 General $4,205 67
2022 General $3,312 40
2021 General $7,755 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Blaine Carmichael
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Blaine Carmichael were reported at $88. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Blaine Carmichael Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $7,755 $132 $37–$438 $132
2022 $3,312 $155 $48–$522 $149
2023 $4,205 $167 $52–$557 $160
2024 $395 $178 $55–$600 $164
2025 $88 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $13,473 136 payments
  2. Allergan Inc. $750 1 payment
  3. Novo Nordisk Inc $276 12 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $215 8 payments
  5. Biohaven Pharmaceuticals, Inc. $138 4 payments
  6. AstraZeneca Pharmaceuticals LP $136 4 payments
  7. Lilly USA, LLC $110 6 payments
  8. GlaxoSmithKline, LLC. $106 6 payments
  9. Avanir Pharmaceuticals, Inc. $98 5 payments
  10. Medtronic, Inc. $84 1 payment
  11. Other $369 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,681 12 payments
  2. Food and Beverage $2,885 182 payments
  3. Travel and Lodging $189 8 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $12,139 78 payments
  2. QULIPTA $5,001 27 payments
  3. VRAYLAR $451 43 payments
  4. Ozempic $240 9 payments
  5. Kerendia $215 8 payments
  6. NURTEC ODT $163 5 payments
  7. AIRSUPRA $122 3 payments
  8. RYBELSUS $116 8 payments
  9. TRELEGY ELLIPTA $106 6 payments
  10. NUEDEXTA $98 5 payments
  11. Other $872 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

2,208

Median for Physician Assistant: 241

Drug cost

$114,167

Median for Physician Assistant: $4,110

Branded share of claims

16.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 17 $26,642
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $21,468
Farxiga Dapagliflozin Propanediol Brand 11 $16,470
Eliquis Apixaban Brand 11 $13,905
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $11,053
Atorvastatin Calcium Generic 131 $1,355
Metoprolol Succinate Generic 77 $1,246
Rosuvastatin Calcium Generic 86 $1,161
Gabapentin Generic 53 $1,082
Albuterol Sulfate Hfa Albuterol Sulfate Brand 44 $1,051

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$15,689

Medicare's payments for the services billed

Medicare patients

178

Average age 74

Services billed

445

87 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 30%
Ischemic heart disease 25%
Chronic kidney disease 21%
Atrial fibrillation 15%
Depression 15%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $215
$215 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $33
$33 — —
VRAYLAR
  • AbbVie, Inc. $31
$31 — —
QULIPTA
  • AbbVie, Inc. $31
$31 — —
MOUNJARO
  • Lilly USA, LLC $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record